丁酰化修饰在恶性肿瘤中作用的研究进展

doi:10.16352/j.issn.1001-6325.2025.11.1496

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (11): 1496-1500.doi: 10.16352/j.issn.1001-6325.2025.11.1496

丁酰化修饰在恶性肿瘤中作用的研究进展

石冬雪, 王瑞涵, 吕蓓蓓, 林晓燕^*

山东第一医科大学附属省立医院病理科,山东济南 250021

收稿日期:2024-12-30 修回日期:2025-03-25 出版日期:2025-11-05 发布日期:2025-10-24
通讯作者: ^*linxiaoyanyan@163.com
基金资助:
国家自然科学基金(82103490,81972474)

Research progress on the role of butyrylation modification in malignant tumors

SHI Dongxue, WANG Ruihan, LYU Beibei, LIN Xiaoyan^*

Department of Pathology,Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China

Received:2024-12-30 Revised:2025-03-25 Online:2025-11-05 Published:2025-10-24
Contact: ^*linxiaoyanyan@163.com

摘要/Abstract

摘要： 丁酰化(Kbu)作为一种重要的蛋白质翻译后修饰(PTM),通过调控蛋白的结构与功能,精细调控肿瘤细胞的多种生物学行为。丁酰化通过调控蛋白质稳定性、酶活性、细胞信号通路、染色质结构和基因表达,其异常促进肿瘤细胞增殖和迁移,进一步参与肿瘤发生发展。本综述重点阐述丁酰化修饰在多种人类肿瘤发生发展中的作用,旨在总结丁酰化修饰在肿瘤领域的研究进展,以期对丁酰化修饰的干预策略有望为肿瘤治疗提供新的方向。

关键词: 丁酰化, 恶性肿瘤, 翻译后修饰

Abstract: Butyrylation (Kbu), as an important post-translational modification (PTM) of proteins, precisely regulates various biological behaviors of tumor cells by modulating the structure and function of proteins. Abnormal butyrylation promotes tumor cell proliferation and migration by regulating protein stability, enzyme activity, cell signaling pathways, chromatin structure and gene expression, and further participates in tumor occurrence and development. This review focuses on the role of butyrylation modification in the occurrence and development of various human tumors, aiming to summarize the research progress of butyrylation modification in the field of tumors, and to provide new directions for tumor treatment through the intervention strategies of butyrylation modification.

Key words: butyrylation, malignant tumor, post-translational modification

中图分类号:

R73-3

石冬雪, 王瑞涵, 吕蓓蓓, 林晓燕. 丁酰化修饰在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2025, 45(11): 1496-1500.

SHI Dongxue, WANG Ruihan, LYU Beibei, LIN Xiaoyan. Research progress on the role of butyrylation modification in malignant tumors[J]. Basic & Clinical Medicine, 2025, 45(11): 1496-1500.

参考文献

[1] Shang S,Liu J,Hua F. Protein acylation: mechanisms,biological functions and therapeutic targets[J]. Signal Transduct Target Ther,2022,7: 396. doi:10.1038/s41392-022-01245-y.
[2] Zhu Z,Han Z,Halabelian L,et al. Identification of lysine isobutyrylation as a new histone modification mark[J]. Nucleic Acids Res,2021,49: 177-189.
[3] Dong H,Zhao Y,Bi C,et al. TmcA functions as a lysine 2-hydroxyisobutyryltransferase to regulate transcription[J]. Nat Chem Biol,2022,18: 142-151.
[4] Huang H,Tang S,Ji M,et al. P300-mediated lysine 2-hydroxyisobutyrylation regulates glycolysis[J]. Mol Cell,2018,70: 663-678.
[5] Huang H,Zhang D,Weng Y,et al. The regulatory enzymes and protein substrates for the lysine β-hydroxybutyrylation pathway[J]. Sci Adv,2021,7. doi:10.1126/sciadv.abe2771.
[6] Zhou T,Cheng X,He Y,et al. Function and mechanism of histone β-hydroxybutyrylation in health and disease[J]. Front Immunol,2022,13: 981285. doi:10.3389/fimmu.2022.981285.
[7] Dmitrieva-posocco O,Wong AC,Lundgren P,et al. β-hydroxybutyrate suppresses colorectal cancer[J]. Nature,2022,605: 160-165.
[8] Shahar N,Larisch S. Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance[J]. Drug Resist Updat,2020,52: 100712. doi:10.1016/j.drup.2020.100712.
[9] He Y,Zheng CC,Yang J,et al. Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance[J]. Cell Discov,2023,9: 74. doi:10.1038/s41421-023-00570-y.
[10] Liao L He Y,Li SJ,et al. Lysine 2-hydroxyisobutyryla-tion of NAT10 promotes cancer metastasis in an ac4C-dependent manner[J]. Cell Res,2023,33: 355-371.
[11] Fioravanti R,Mautone N,Rovere A,et al. Targeting histone acetylation/deacetylation in parasites: an update (2017—2020)[J]. Curr Opin Chem Biol,2020,57: 65-74.
[12] Chen SH,Hsiao SY,Chang KY,et al. New insights into oral squamous cell carcinoma: from clinical aspects to molecular tumorigenesis[J]. Int J Mol Sci,2021,22. doi:10.3390/ijms22052252.
[13] Zhang Z,Xie H,Zuo W,et al. Lysine 2-hydroxyisobutyrylation proteomics reveals protein modification alteration in the actin cytoskeleton pathway of oral squamous cell carcinoma[J]. J Proteomics,2021,249: 104371. doi:10.1016/j.jprot.2021.104371.
[14] Xu G,Wang J,Wu Z,et al. SAHA regulates histone acetylation,butyrylation,and protein expression in neuro-blastoma[J]. J Proteome Res,2014,13: 4211-4219.
[15] Doll S,Urisman A,Oses-prieto A,et al. Quantitative proteomics reveals fundamental regulatory differences in oncogenic HRAS and isocitrate dehydrogenase (IDH1) driven astrocytoma[J]. Mol Cell Proteomics,2017,16: 39-56.
[16] Bray F,Laversanne M,Sung H,et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74: 229-263.
[17] Zhang Z,Wang Y,Liang Z,et al. Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression[J]. iScience,2023,26: 108142. doi:10.1016/j.isci.2023.108142.
[18] Zheng RS,Chen R,Han BF,et al. Cancer incidence and mortality in China,2022[J]. Chin J Oncol,2024,46: 221-231.
[19] Lu Y,Li X,Zhao K,et al. Global landscape of 2-hydroxyisobutyrylation in human pancreatic cancer[J]. Front Oncol,2022,12: 1001807. doi:10.3389/fonc.2022.1001807.
[20] Tsuboi M,Herbst RS,John T,et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC[J]. N Engl J Med,2023,389: 137-147.
[21] Huang J,Liang L,Jiang S,et al. BDH1-mediated LRRC31 regulation dependent on histone lysine β-hydroxybutyry-lation to promote lung adenocarcinoma progression[J]. MedComm (2020),2023,4: e449. doi:10.1002/mco2.449.
[22] Xia C,Dong X,Li H,et al. Cancer statistics in China and United States,2022: profiles,trends,and determinants[J]. Chin Med J (Engl),2022,135: 584-590.
[23] Zhao LN,Yuan HF,Wang YF,et al. IFN-α inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver[J]. Acta Pharmacol Sin,2022,43: 1484-1494.
[24] Zhang H,Chang Z,Qin LN,et al. MTA2 triggered Rloop transregulates BDH1-mediated β-hydroxybutyryla-tion and potentiates propagation of hepatocellular carcinoma stem cells[J]. Signal Transduct Target Ther,2021,6: 135. doi:10.1038/s41392-021-00464-z.

丁酰化修饰在恶性肿瘤中作用的研究进展

Research progress on the role of butyrylation modification in malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

本文评价

[1]	凌彩霞, 王春芳, 罗艳红. TMEM基因家族在肿瘤发生发展中的作用[J]. 基础医学与临床, 2025, 45(9): 1243-1247.
[2]	阳晶晶, 马艳, 王悦, 孙阳, 李盼, 郭峰. ACE2蛋白Cys141、Cys344和Cys498位点的棕榈酰化修饰促进其在细胞外囊泡的定位[J]. 基础医学与临床, 2025, 45(9): 1151-1157.
[3]	秦怡, 王晓燕. 蛋白酪氨酸激酶-2在妇科肿瘤中的作用[J]. 基础医学与临床, 2025, 45(8): 1098-1102.
[4]	瞿瑛, 毛彩云, 钟晴, 张蓉, 宋运佳. Keap1翻译后修饰调控氧化应激相关疾病[J]. 基础医学与临床, 2025, 45(1): 107-111.
[5]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[6]	吴玉红, 喻才元, 叶石才. NMES1基因在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 403-407.
[7]	候壹颖, 魏芳. BUB1B与妇科恶性肿瘤[J]. 基础医学与临床, 2024, 44(12): 1717-1721.
[8]	邹宇祥, 唐慧. TLR2在消化道肿瘤发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1304-1308.
[9]	徐周纬严尚学吴华勋陈镜宇张影魏伟. G蛋白偶联受体激酶2活性和表达的调控及其在恶性肿瘤中的作用[J]. 基础医学与临床, 2017, 37(4): 548-552.
[10]	高增法吴永娜李汛. HACE1的生物学特性及其在恶性肿瘤的研究进展[J]. 基础医学与临床, 2016, 36(3): 396-400.
[11]	高增法吴永娜李汛. ARID1A在恶性肿瘤中的研究进展[J]. 基础医学与临床, 2015, 35(9): 1267-1270.
[12]	陈志刚纪志刚石冰冰严维刚王清海樊华李汉忠刘洋. 2例钙化性肾脏肿物的诊治分析[J]. 基础医学与临床, 2015, 35(9): 1249-1251.